Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
Clinical trial NCT02743611 · TERMINATED
Trial details
- NCT number
- NCT02743611
- Sponsor
- Bellicum Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-14
- Primary completion
- 2019-07-19
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.